The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and F3 NASH patients

Like most tech lovers, I’m excited about the upcoming CES conference.  I won’t be attending in person but will be watching it very closely...

Yesterday marked the 36th year that the world observed World No Tobacco Day. This relatively obscure milestone masks a stalled effort to curb consumption of combustible cigarettes and other nicotine-related products. It’s unlikely most people paid any attention. But the impact of smoking is all around us, even if we don’t see it. Statistics rarely tell a provocative story to compel people to action.

I thought it would be fun to look back at some of my predictions for health tech from almost a decade ago in Forbes....